Lee-Cheng (L-C) Liu, President and CEO of EirGenix, one of Taiwan’s fastest growing companies in the biotech field, documents the progress made in the set-up of EirGenix’s new commercial biomanufacturing plant, which will become the largest facility of this kind in Taiwan, while the company is about to start the phase III clinical trial of its own trastuzumab biosimilar and is actively looking for strong commercial partners to distribute it in all international markets, with a market entry set up for 2020.
EirGenix’s business model is based on two main pillars: contract development and manufacturing (CD&M) services and the development of our own pipeline of biosimilars. What would you highlight as EirGenix’s main achievements in these two fields?
"We want to ensure that this world-class facility, which will stand as Taiwan’s largest biomanufacturing plant, will be up and running by the third quarter of 2018."
